Melanoma Clinical Trials in Pittsburgh

Showing 181-200 of 329 trials

Live Biotherapeutic Product MRx0518 and Pembrolizumab Combination Study in Solid Tumors

NCT03637803

This is an open label, safety and preliminary efficacy study of MRx0518 in combination with pembrolizumab in patients with solid tumours (non small cell lung cancer, renal cell carcinoma, bladder cancer or melanoma). Subjects will be treated with IV pembrolizumab every 3 weeks and 1 capsule twice daily of MRx0518. Treatment will continue as long as clinically relevant, until disease progression, unacceptable AEs or withdrawal of consent up to a maximum of 35 cycles (approx. 2 years).

OncologySolid TumorNon Small Cell Lung Cancer+3 more

4D pharma plc63 participantsStarted Jan 2019

Kansas City, Kansas, United States • Pittsburgh, Pennsylvania, United States • Houston, Texas, United States +2 more locations

TERMINATEDPhase 3< 1 mile

Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence

NCT04410445

The main purpose of this study is to compare the efficacy of bempegaldesleukin plus nivolumab versus nivolumab in patients with completely resected Stage IIIA/B/C/D, or Stage IV cutaneous melanoma who are at high risk for recurrence.

MelanomaMelanoma Stage IIIMelanoma Stage IV+1 more

Nektar Therapeutics765 participantsStarted Jul 2020

Scottsdale, Arizona, United States • Little Rock, Arkansas, United States • Anaheim, California, United States +209 more locations

Live Biotherapeutic Product MRx0518 and Pembrolizumab Combination Study in Solid Tumors

Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence

Melanoma Trials in Other Cities

A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors

A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer

Pembrolizumab With Talimogene Laherparepvec or Placebo in Unresected Melanoma

A Prospective Multicenter Sample Collection Study Using Non-invasive Methods to Investigate Mutation Burden in Non-lesional Facial Skin of Patients With a Hx of Skin Cancer

A Study of Cobimetinib Plus Atezolizumab Versus Pembrolizumab in Participants With Previously Untreated Advanced BRAFv600 Wild-Type Melanoma

Safety Study of SEA-CD40 in Cancer Patients

Study of ONCR-177 Alone and in Combination With PD-1 Blockade in Adult Subjects With Advanced and/or Refractory Cutaneous, Subcutaneous or Metastatic Nodal Solid Tumors or With Liver Metastases of Solid Tumors

A Study of PLX2853 in Advanced Malignancies.

A Study of Two Different Dose Combinations of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated, Unresectable or Metastatic Melanoma

Phase I/II Study of PDR001 in Patients With Advanced Malignancies

A Platform Study of Novel Immunotherapy Products in Participants With Previously Treated Unresectable or Metastatic Cutaneous Melanoma

A Study of RO7293583 in Participants With Unresectable Metastatic Tyrosinase Related Protein 1 (TYRP1)-Positive Melanomas

Ipilimumab and Nivolumab as Adjuvant Treatment of Mucosal Melanoma

A Study of ADXS-NEO Expressing Personalized Tumor Antigens

Engaging Moms on Teen Indoor Tanning Through Social Media

Study of ASN003 in Subjects With Advanced Solid Tumors

Trial of PI-88 With Dacarbazine in Patients With Metastatic Melanoma

Diagnostic Imaging Study for the Melanoma Advanced Imaging Dermatoscope (mAID)

Other Conditions in Pittsburgh